Dr. Günter Harms
Dr. Günter Harms is a pharmaceutical executive and healthcare professional with a proven track record of bringing innovative therapies to patients. His expertise includes the development, launch, and lifecycle management of medicines, with a particular focus on orphan drugs and pioneering access to gene therapies.
At Novartis and Avexis, he played a pivotal role in advancing and implementing strategies that shaped the early field of gene therapy. Dr. Harms is a Partner at ORPHAN NOW, where he supports rare disease companies in developing and commercializing much-needed therapies. Furthermore, he held leadership roles at Shire, Ferring, and the former Institute for Health Systems Research, a WHO collaborating centre. He is passionate about improving patient access to innovation.
Gene and Cell therapies (GCTs) are transforming medicine. By addressing diseases at their genetic root cause, these therapies offer the potential for more effective and long-lasting treatments of some of the most severe, rare, and chronic conditions. However, turning these scientific breakthroughs into accessible treatments presents significant challenges. High development and manufacturing costs, small patient populations, and uncertainty about long-term outcomes create obstacles for health technology assessments, pricing and reimbursement. This session will cover practical market access approaches such as real-world evidence, HTA reforms, and novel payment models to ensure that breakthrough therapies can reach patients sustainably. It is designed to equip researchers, developers, and stakeholders with an understanding of the commercial realities shaping the future of GCTs.
Online via MS Teams | Please register HERE!
This lecture series is part of the National Strategy for Gene- and Cell-based Therapies.
The organizers reserve the right to change and update the topics and speakers.
All webinars with automatic captioning.
